Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21533701 | 0.86 | TGM2 (0.43) | NPSR1KDM4EKMT2ASMN1; SMN2TGM2 | |
| SCHEMBL21171896 | 0.82 | NPSR1 (0.40) | NPSR1KDM4EKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL21172160 | 0.82 | IDO1 (0.44) | NPSR1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL21171890 | 0.81 | KDM4E (0.41) | NPSR1KDM4EKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL21533659 | 0.81 | ALDH1A1 (0.48) | NPSR1KDM4EKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL21172134 | 0.80 | HDAC3 (0.39) | KDM4EKMT2ASMN1; SMN2TGM2CYP1A2 | |
| SCHEMBL21171743 | 0.79 | HDAC3 (0.47) | NPSR1KDM4EKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL24487057 | 0.79 | TGM2 (0.43) | NPSR1KDM4EKMT2ASMN1; SMN2RAB9A | |
| SCHEMBL24487059 | 0.79 | TGM2 (0.40) | NPSR1KDM4EKMT2ASMN1; SMN2RAB9A | |
| SCHEMBL21171721 | 0.79 | RAB9A (0.42) | NPSR1KDM4EKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11353461-B2 | Methods of enhancing MS detection of tagged glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190219587-A1 | METHODS OF ENHANCING MS DETECTION OF TAGGED GLYCANS | WATERS TECHNOLOGIES CORPORATION | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | NPSR1 584/4885KDM4E 3466/4885KMT2A 2258/4885 |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | FUT5, FUT6, OGT | NPSR1 584/4885KDM4E 3466/4885KMT2A 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.